Reviewed by Emily Henderson, B.Sc.Apr 1 2020 The Patient-Centered Outcomes Research Institute has funded up to $50 million to evaluate hydroxychloroquine (HCQ) as a preventive drug for the novel coronavirus. The funding creates a new rapid-response study designed and led by the Duke Clinical Research Institute (DCRI) which seeks to engage healthcare workers across the